N Jewel Samadder1, Karen Curtin2, Jathine Wong3, Thérèse M F Tuohy3, Geraldine P Mineau4, Ken Robert Smith3, Richard Pimentel3, Lisa Pappas3, Ken Boucher3, Ignacio Garrido-Laguna5, Dawn Provenzale6, Randall W Burt7. 1. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Medicine (Gastroenterology), University of Utah, Salt Lake City, Utah. Electronic address: jewel.samadder@hsc.utah.edu. 2. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Medicine (Genetic Epidemiology), University of Utah, Salt Lake City, Utah. 3. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 4. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah. 5. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Medicine (Medical Oncology), University of Utah, Salt Lake City, Utah. 6. Veterans Affairs Cooperative Studies Epidemiology Center-Durham, Durham Veterans Affairs Medical Center, Durham, North Carolina; Department of Medicine (Gastroenterology), Duke University, Durham, North Carolina. 7. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Medicine (Gastroenterology), University of Utah, Salt Lake City, Utah; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.
Abstract
BACKGROUND & AIMS: Patients diagnosed with colorectal cancer (CRC) are at risk for synchronous and metachronous lesions at the time of diagnosis or during follow-up evaluation. We performed a population-based study to evaluate the rate, predictors, and familial risk for synchronous and metachronous CRC in Utah. METHODS: All newly diagnosed cases of CRC between 1980 and 2010 were obtained from the Utah Cancer Registry and linked to pedigrees from the Utah Population Database. RESULTS: Of the 18,782 patients diagnosed with CRC, 134 were diagnosed with synchronous CRC (0.71%) and 300 were diagnosed with metachronous CRC (1.60%). The risk for synchronous CRC was significantly higher in men (odds ratio [OR], 1.45; 95% confidence interval [CI], 1.02-2.06) and in patients aged 65 years or older (OR, 1.50; 95% CI, 1.02-2.21). Synchronous CRCs were located more often in the proximal colon (OR, 1.70; 95% CI, 1.20-2.41). First-degree relatives of cases with synchronous (OR, 1.86; 95% CI, 1.37-2.53), metachronous (OR, 2.34; 95% CI, 1.62-3.36), or solitary CRC (OR, 1.75; 95% CI, 1.63-1.88) were at increased risk for developing CRC, compared with relatives of CRC-free individuals. Four percent of first-degree relatives of patients with synchronous or metachronous cancer developed CRC at younger ages than the age recommended for initiating CRC screening (based on familial risk), and therefore would not have been screened. CONCLUSIONS: Of patients diagnosed with CRC, 2.3% are found to have synchronous lesions or develop metachronous CRC during follow-up evaluation. Relatives of these patients have a greater risk of CRC than those without a family history of CRC. These results highlight the importance of obtaining a thorough family history and adhering strictly to surveillance guidelines during management of high-risk patients.
BACKGROUND & AIMS:Patients diagnosed with colorectal cancer (CRC) are at risk for synchronous and metachronous lesions at the time of diagnosis or during follow-up evaluation. We performed a population-based study to evaluate the rate, predictors, and familial risk for synchronous and metachronous CRC in Utah. METHODS: All newly diagnosed cases of CRC between 1980 and 2010 were obtained from the Utah Cancer Registry and linked to pedigrees from the Utah Population Database. RESULTS: Of the 18,782 patients diagnosed with CRC, 134 were diagnosed with synchronous CRC (0.71%) and 300 were diagnosed with metachronous CRC (1.60%). The risk for synchronous CRC was significantly higher in men (odds ratio [OR], 1.45; 95% confidence interval [CI], 1.02-2.06) and in patients aged 65 years or older (OR, 1.50; 95% CI, 1.02-2.21). Synchronous CRCs were located more often in the proximal colon (OR, 1.70; 95% CI, 1.20-2.41). First-degree relatives of cases with synchronous (OR, 1.86; 95% CI, 1.37-2.53), metachronous (OR, 2.34; 95% CI, 1.62-3.36), or solitary CRC (OR, 1.75; 95% CI, 1.63-1.88) were at increased risk for developing CRC, compared with relatives of CRC-free individuals. Four percent of first-degree relatives of patients with synchronous or metachronous cancer developed CRC at younger ages than the age recommended for initiating CRC screening (based on familial risk), and therefore would not have been screened. CONCLUSIONS: Of patients diagnosed with CRC, 2.3% are found to have synchronous lesions or develop metachronous CRC during follow-up evaluation. Relatives of these patients have a greater risk of CRC than those without a family history of CRC. These results highlight the importance of obtaining a thorough family history and adhering strictly to surveillance guidelines during management of high-risk patients.
Authors: Charles J Kahi; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas J Robertson; Douglas K Rex Journal: Am J Gastroenterol Date: 2016-02-12 Impact factor: 10.864
Authors: David A Drew; Reiko Nishihara; Paul Lochhead; Aya Kuchiba; Zhi Rong Qian; Kosuke Mima; Katsuhiko Nosho; Kana Wu; Molin Wang; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino Journal: Am J Gastroenterol Date: 2017-01-24 Impact factor: 10.864
Authors: Divyanshoo R Kohli; Ken Robert Smith; Jathine Wong; Zhe Yu; Kenneth Boucher; Douglas O Faigel; Rahul Pannala; Randall W Burt; Karen Curtin; N Jewel Samadder Journal: J Gastroenterol Date: 2019-06-25 Impact factor: 7.527
Authors: N Jewel Samadder; Ken Robert Smith; Jathine Wong; Heidi Hanson; Kenneth Boucher; Randall W Burt; Michael Charlton; Kathryn R Byrne; Juan F Gallegos-Orozco; Cathryn Koptiuch; Karen Curtin Journal: Dig Dis Sci Date: 2016-09-21 Impact factor: 3.199
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059